Extended surgery in treatment of patients with locally advanced pancreatic cancer and predictor of postoperative complications
DOI:
https://doi.org/10.24144/2415-8127.2018.57.75-82Keywords:
Pancreatic tumors, extended pancreatic resections, locally advanced pancreatic cancer, sarcopenia.Abstract
Introduction. Due to locoregional growth and early systemic spread of pancreatic adenocarcinoma, local invasion of the major vessels and adjacent organs, the presence of distant metastasis often limits tumor resectability. Extended resections of pancreatic tumors is the only opportunity for their radical treatment. Aim. To improve the results of treatment of patients with pancreatic tumors by determining of place of extended resections in the treatment of patients with locally advanced pancreatic tumors, metabolic factors of the risk of postoperative complications and mortality, and to develop methods for their prevention. Matherials and methods. In the period 2010-2017 we performed 618 resections in patients with pancreatic adenocarcinoma: distal pancreatectomy – in 139 (22,5%), pancreaticoduodenectomy – in 462 (74,8%) and total pancreatectomy– in 17 (2,7%) patients. EP were performed in 142 (23,0%) patients: pancreaticoduodenectomy – in 77 (54,2%), distal resections – in 54 (38,0%), pancreatectomy – in 11 (7,8%). 87 patient were examined using CT for sarcopenia. According to TPI sarcopenia was diagnosed in 38 (43,7%) patients, according to HUAC – in 35 (40,2%). Results and their discussion. Postoperetive complications occurred in 182 patients (38,2%) in the standard resection group and in 58 (40,8%) in the group with extended resections (????2 = 0,3 p=0,57). Mortality was 2,3%, 14 patients died: 5 (3,5%) – after extended resections and 9 (1,9%) – after standard pancreatectomy (????2 = 1,3, p=0,25). Median survival and 5-year overall survival rate were reduced in patients having extended pancreatectomy compared with those undergoing a standard resection (21 months, 26% and 28 months, 29%), ????2 = 0,15, p=0,69. The presence of sarcopenia is a reliable risk factor for postoperative complications ((????2 = 7,3, p=0,006 and ????2 = 4,47, p=0,03, p<0,05). Conclusions. Extended resection of the pancreas is possible and it can increase the number of radically operated patients. Mortality, postoperative complications, long-term results of treatment after extended resection of pancreas are comparable with standard resections. Sarcopenia can be used to predict and prevent the postoperative complications, as well as to improve the selection of patients before pancreatic resection in patients with pancreatic tumors.
References
Kaiser J, Hackert T, Buchler MW. Extended pancreatectomy: does it have a role in the contemporary management of pancreatic adenocarcinoma? Dig Surg. 2017;34:441-6. DOI: 10.1159/000478539.
Hartwig W, Gluth A, Hinz U, Koliogiannis D, Strobel O, Hackert T, et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Br J Surg. 2016 Nov;103(12):1683-94. DOI: 10.1002/bjs.10221.
Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer – how to improve long-term survival. World J of Gastrointest Oncol. 2016;8(3):248-57. DOI: 10.4251/wjgo. v8.i3.248.
Kasumova GG, Conway WC, Tseng JF. The role of venous and arterial resection in pancreatic cancer surgery. Ann Surg Oncol. 2018 Jan;25(1):51-8. DOI: 10.1245/s10434-016-5676-3.
Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 2014;156:1-14. DOI: 10.1016/i.surg.2014.02.009.
Petrucciani N, Debs T, Nigri G, Giannini G., Sborlini E, Kassir R, et al. Pancreatectomy combined with multivisceral resection for pancreatic malignancies: is it justified? Results of a systematic review. HPB. 2018 Jan;20(1):3-10. DOI: 10.1016/j.hpb.2017.08.002.
Joglekar S, Asghar A, Mott S, Johnson B, Button A, Clark E, et al. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015 May;111(6):771-5. DOI: 10.1002/jso.23862.
Jones K, Gordon-Weeks A, Coleman C, Silva M. Radiologically determined sarcopenia predicts morbidity and mortality following abdominal surgery: A systematic review and meta-analysis. World J Surg. 2017;41:2266-79. DOI: 10.1007/s00268-017-3999-2.
Klompmaker S, van Hilst J, Gerritsen SL, Adham M, Quer TA, Bassi C, et al. Outcomes after distal pancreatectomy with celiac axis resection for pancreatic cancer: A Pan-European retrospective cohort study. Annals of Surgical Oncology. 2018 May;25(5):1440-7. DOI: 10.1245/s10434-018-6391-z.
Selvaggi F, Mascetta G, Daskalaki D, Molin M, Salvia R., Butturini G. Outcome of superior mesentericportal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study. Langenbeck’s Arch Surg. 2014;399:659-65. DOI:10.1007/s00423-014-1194-6.
Ohgi K, Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R. Is pancreatic head cancer with portal venous involvement really borderline resectable? Appraisal of an upfront surgery series. Ann Surg Oncol. 2017 Sep; 24(9):2752-61. DOI: 10.1245/s10434-017-5972-6.
